# Phase 1 mesothelioma trials recruiting: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1 for mesothelioma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 mesothelioma trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/mesothelioma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 20, 2026 | NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Treeline Biosciences, Inc. | Phase 1 | Recruiting | Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713732) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| March 2, 2026 | NCT07443020 | Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 1 | Recruiting | Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443020) |
| December 11, 2025 | NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | IDEAYA Biosciences | Phase 1 | Recruiting | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277413) |
| September 25, 2025 | NCT07192900 | Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease | Sponsor not shown (see the record) | Phase 1 | Recruiting | Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192900) |
| March 20, 2025 | NCT06885697 | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | National Cancer Institute (NCI) | Phase 1 | Recruiting | Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885697) |
| December 10, 2024 | NCT06726564 | A Study of MT027 in Patients with Pleural Malignant Tumors | Suzhou Maximum Bio-tech Co., Ltd. | Phase 1 | Recruiting | Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma, Pleural Malignant... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06726564) |
| October 22, 2024 | NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors | Aromics Therapeutics | Phase 1 | Not yet recruiting | Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06652529) |
| June 11, 2024 | NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | BridGene Biosciences Inc. | Phase 1 | Recruiting | Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06452160) |
| June 6, 2024 | NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors | KaliVir Immunotherapeutics | Phase 1 | Recruiting | Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06444815) |
| February 9, 2024 | NCT06251310 | SW-682 in Advanced Solid Tumors | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Phase 1 | Recruiting | Advanced Solid Tumor, Mesothelioma, Malignant | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06251310) |
| January 9, 2024 | NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 | Recruiting | Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma, CAR-T Cell Therapy, Solid Tumor, Adult | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06196294) |
| January 26, 2023 | NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours | Mabpro, a.s. | Phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer, Head and Neck Cancer, Non-small-cell... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05698238) |
| November 28, 2022 | NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | A&G Pharmaceutical Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05627960) |
| October 6, 2022 | NCT05568680 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Verismo Therapeutics | Phase 1 | Recruiting | Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05568680) |
| March 31, 2022 | NCT05304208 | dENdritic Cell Therapy Combined With SURgEry in Mesothelioma | Erasmus Medical Center | Phase 1 | Recruiting | Mesotheliomas Pleural | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05304208) |
| February 18, 2022 | NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Bristol-Myers Squibb | Phase 1 | Recruiting | Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic... | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05245500) |
| November 4, 2021 | NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | Nurix Therapeutics, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell... | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05107674) |
| April 16, 2019 | NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03917043) |
| November 30, 2018 | NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Mesotheliomas Pleural | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03760575) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| IDEAYA Biosciences | 1 |
| Nurix Therapeutics, Inc. | 1 |
| Suzhou Maximum Bio-tech Co., Ltd. | 1 |
| Mabpro, a.s. | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Verismo Therapeutics | 1 |
| National Cancer Institute (NCI) | 1 |
| Treeline Biosciences, Inc. | 1 |
| Aromics Therapeutics | 1 |
| BridGene Biosciences Inc. | 1 |
| KaliVir Immunotherapeutics | 1 |
| Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 1 |
| SHY Therapeutics | 1 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| A&G Pharmaceutical Inc. | 1 |
| Erasmus Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| China | 3 |
| South Korea | 1 |
| United Kingdom | 1 |
| Australia | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
- [Law schools in the United States](https://specstream.ai/data/businesses/law-schools/united-states)
- [Waste collection companies in the United States](https://specstream.ai/data/businesses/waste-collection-companies/united-states)
- [Ferry boat companies in the United States](https://specstream.ai/data/businesses/ferry-boat-companies/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
